HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Androgen receptor expression: prognostic value in locally advanced squamous cell carcinoma of the head and neck.

AbstractBACKGROUND AND PURPOSE:
This study investigated the prognostic value of androgen receptor (AR) expression of tumor cells in patients treated with surgery and subsequent radio(chemo)therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
MATERIAL AND METHODS:
The impact of AR and 11 additional factors on locoregional control (LRC), metastases-free survival (MFS), and overall survival (OS) was retrospectively studied in 163 patients with nonmetastatic stage III/IV SCCHN. Additional factors included age, gender, ECOG performance status, pre-radiotherapy (pre-RT) hemoglobin levels, tumor site, histologic grade, T category, N category, HPV status, extent of resection, and concurrent chemotherapy.
RESULTS:
On multivariate analysis, improved LRC was significantly associated with pre-RT hemoglobin levels≥12 g/dl (risk ratio [RR] 2.22; 95% confidence interval [CI] 1.19–4.13; p=0.013), tumor site (RR 1.39; 95% CI 1.14–1.70; p=0.001), lower T category (RR 1.67; 95% CI 1.18–2.44; p=0.003), and lower N category (RR 4.18; 95% CI 1.90–10.55; p<0.001). Improved MFS was associated with AR expression (RR 2.21; 95% CI 1.01–5.41; p=0.048), better ECOG performance status (RR 3.19; 95% CI 1.50–7.14; p=0.003), lower T category (RR 2.24; 95% CI 1.47–3.65; p<0.001), and lower N category (RR 5.33; 95% CI 2.07–16.63; p<0.001). OS was positively associated with AR expression (RR 1.99; 95% CI 1.06–4.00; p=0.032), better ECOG performance status (RR 2.20; 95% CI 1.20–4.09; p=0.010), pre-RT hemoglobin levels≥12 g/dl (RR 2.13; 95% CI 1.19–3.82; p=0.012), lower T category (RR 1.81; 95% CI 1.30–2.62; p<0.001), and lower N category (RR 3.41; 95% CI: 1.65–7.80; p<0.001).
CONCLUSION:
Tumor cell expression of AR was an independent prognostic factor for MFS and OS and should be considered in future prospective trials.
AuthorsD Rades, N D Seibold, S E Schild, K L Bruchhage, M P Gebhard, F Noack
JournalStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (Strahlenther Onkol) Vol. 189 Issue 10 Pg. 849-55 (Oct 2013) ISSN: 1439-099X [Electronic] Germany
PMID23959264 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • Receptors, Androgen
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (analysis)
  • Carcinoma, Squamous Cell (chemistry, mortality, pathology)
  • Female
  • Germany (epidemiology)
  • Head and Neck Neoplasms (chemistry, mortality, pathology)
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Prognosis
  • Receptors, Androgen (analysis)
  • Reproducibility of Results
  • Risk Assessment
  • Sensitivity and Specificity
  • Squamous Cell Carcinoma of Head and Neck
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: